PRODUCT RECALL RESPONSE FORM

URGENT DRUG RECALL- RETAIL

Please complete the required information and fax it to **1-817-868-5362,** or email to **rxrecalls@inmar.com**

To the Attention of Drug Safety/ Recall Services-Zydus Pharmaceuticals USA Inc.

Product	NDC Number	Lot Number	Expiry Date	Count	Distribution Start Date	Distribution End Date
Oxybutynin Chloride Extended-Release Tablets, USP 5 mg	68382-255-01	M212749	11/2024	100's	05/16/2023	05/31/2023
Oxybutynin Chloride Extended-Release Tablets, USP 5 mg	68382-255-01	M214477	11/2024	100's	05/26/2023	06/14/2023
Oxybutynin Chloride Extended-Release Tablets, USP 5 mg	68382-255-01	M214478	11/2024	100's	04/01/2023	06/27/2023
Oxybutynin Chloride Extended-Release Tablets, USP 5 mg	68382-255-01	M214479	11/2024	100's	06/23/2023	07/05/2023
Oxybutynin Chloride Extended-Release Tablets, USP 5 mg	68382-255-01	M214480	11/2024	100's	07/03/2023	07/26/2023
Oxybutynin Chloride Extended-Release Tablets, USP 10 mg	68382-256-01	M213318	11/2024	100's	05/23/2023	06/05/2023
Oxybutynin Chloride Extended-Release Tablets, USP 10 mg	68382-256-01	M213314	11/2024	100's	05/04/2023	05/19/2023
Oxybutynin Chloride Extended-Release Tablets, USP 10 mg	68382-256-01	M213315	11/2024	100's	04/01/2023	05/30/2023
Oxybutynin Chloride Extended-Release Tablets, USP 10 mg	68382-256-01	M214436	11/2024	100's	06/02/2023	06/14/2023

Office of Regulatory Affairs
Zydus Pharmaceuticals (USA) Inc.
(A wholly owned subsidiary of Zydus Lifesciences Limited)
73 Route 31 North • Pennington, NJ 08534 | Phone: 609-730-1900 | Fax: 609-730-1999

Oxybutynin Chloride Extended-Release Tablets, USP 10 mg	68382-256-01	M214437	11/2024	100's	05/25/2023	06/26/2023
Product	**NDC Number**	**Lot Number**	**Expiry Date**	**Count**	**Distribution Start Date**	**Distribution End Date**
Oxybutynin Chloride Extended-Release Tablets, USP 10 mg	68382-256-01	M214438	11/2024	100's	06/16/2023	06/30/2023
Oxybutynin Chloride Extended-Release Tablets, USP 10 mg	68382-256-01	M300653	12/2024	100's	06/24/2023	07/12/2023
Oxybutynin Chloride Extended-Release Tablets, USP 10 mg	68382-256-01	M300654	12/2024	100's	07/03/2023	07/25/2023
Oxybutynin Chloride Extended-Release Tablets, USP 15 mg	68382-257-01	M211541	10/2024	100's	03/31/2023	04/24/2023
Oxybutynin Chloride Extended-Release Tablets, USP 15 mg	68382-257-01	M211542	10/2024	100's	04/24/2023	05/22/2023
Oxybutynin Chloride Extended-Release Tablets, USP 15 mg	68382-257-01	M212746	10/2024	100's	05/19/2023	06/14/2023
Oxybutynin Chloride Extended-Release Tablets, USP 15 mg	68382-257-01	M300660	12/2024	100's	06/13/2023	07/12/2023

No. of Returns kit required: _____

Please mark as applicable

__ We currently do not have any inventory of the above-listed Lot/bottles

__ We are notifying our customers

__ We have identified and notified my customers that were shipped or may have been shipped this product by_____;

__ Attached is the list of customers who received/ may have received this product. Please notify my customers.

Any adverse event associated with recalled product? ___ Yes ___ No

Office of Regulatory Affairs
Zydus Pharmaceuticals (USA) Inc.
(A wholly owned subsidiary of Zydus Lifesciences Limited)
73 Route 31 North • Pennington, NJ 08534 | Phone: 609-730-1900 | Fax: 609-730-1999

If yes, please explain:

Please check appropriate box to describe your business

___ Wholesaler/Distributor

___ Retailers

___ Repackager

___ Manufacturer

___ Pharmacy- Retail

___ Hospital/ Medical Facility

___ Hospital Pharmacies

___ Medical Laboratory

___ Other: _____

Name: _____

Title: _____

Tel Number: _____

Firm Name: _____ DEA#_____

Address: _____

City/ State: _____

If you have not purchased, the concerned lot directly from Zydus Pharmaceuticals USA Inc., then please provide details of your wholesaler: _____(Name, City) DEA#_____

Signature: _____ Date: _____

Office of Regulatory Affairs
Zydus Pharmaceuticals (USA) Inc.
(A wholly owned subsidiary of Zydus Lifesciences Limited)
73 Route 31 North • Pennington, NJ 08534 | Phone: 609-730-1900 | Fax: 609-730-1999